Barclays
CLVS

Barclays’s Clovis Oncology, Inc. CLVS Stock Holding History

Barclays’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-132,775
Closed -$158K – 5517
2022
Q3 		$158K Buy
132,775
+94,367
+246% +$147K ﹤0.01% 3337
2022
Q2 		$69K Sell
38,408
-37,866
-50% -$55.9K ﹤0.01% 3922
2022
Q1 		$154K Sell
76,274
-64,972
-46% -$128K ﹤0.01% 3577
2021
Q4 		$383K Buy
141,246
+91,907
+186% +$340K ﹤0.01% 3314
2021
Q3 		$220K Buy
49,339
+26,681
+118% +$129K ﹤0.01% 3571
2021
Q2 		$131K Sell
22,658
-57,577
-72% -$337K ﹤0.01% 3739
2021
Q1 		$563K Buy
80,235
+23,694
+42% +$159K ﹤0.01% 3112
2020
Q4 		$271K Sell
56,541
-78,361
-58% -$396K ﹤0.01% 3592
2020
Q3 		$786K Sell
134,902
-246,204
-65% -$1.47M ﹤0.01% 2893
2020
Q2 		$2.57M Buy
381,106
+287,894
+309% +$2.18M ﹤0.01% 1877
2020
Q1 		$593K Sell
93,212
-21,136
-18% -$170K ﹤0.01% 3447
2019
Q4 		$1.19M Buy
114,348
+82,915
+264% +$603K ﹤0.01% 3517
2019
Q3 		$124K Sell
31,433
-175,503
-85% -$1.42M ﹤0.01% 5323
2019
Q2 		$3.08M Buy
206,936
+134,312
+185% +$2.43M ﹤0.01% 2401
2019
Q1 		$1.8M Sell
72,624
-2,694
-4% -$67.5K ﹤0.01% 2686
2018
Q4 		$1.35M Buy
75,318
+242
+0.3% +$4.95K ﹤0.01% 2806
2018
Q3 		$2.2M Sell
75,076
-4,640
-6% -$180K ﹤0.01% 2764
2018
Q2 		$3.62M Sell
79,716
-17,274
-18% -$840K ﹤0.01% 2009
2018
Q1 		$5.12M Sell
96,990
-65,134
-40% -$3.8M ﹤0.01% 1621
2017
Q4 		$11M Buy
162,124
+141,122
+672% +$9.87M 0.01% 1133
2017
Q3 		$1.73M Sell
21,002
-94,140
-82% -$7.46M ﹤0.01% 2493
2017
Q2 		$10.8M Buy
115,142
+108,721
+1,693% +$6.65M 0.01% 925
2017
Q1 		$410K Sell
6,421
-287,046
-98% -$17.4M ﹤0.01% 3601
2016
Q4 		$13M Buy
293,467
+275,994
+1,580% +$9.71M 0.01% 809
2016
Q3 		$630K Sell
17,473
-6,705
-28% -$144K ﹤0.01% 3040
2016
Q2 		$332K Sell
24,178
-9,408
-28% -$138K ﹤0.01% 3549
2016
Q1 		$638K Buy
33,586
+22,937
+215% +$485K ﹤0.01% 2928
2015
Q4 		$373K Sell
10,649
-12,739
-54% -$822K ﹤0.01% 3430
2015
Q3 		$2.13M Sell
23,388
-41,626
-64% -$3.6M ﹤0.01% 2064
2015
Q2 		$5.66M Buy
65,014
+63,095
+3,288% +$5.4M 0.01% 1395
2015
Q1 		$142K Buy
1,919
+251
+15% +$17.7K ﹤0.01% 4601
2014
Q4 		$94K Sell
1,668
-4,526
-73% -$238K ﹤0.01% 5258
2014
Q3 		$280K Sell
6,194
-84,776
-93% -$3.54M ﹤0.01% 4449
2014
Q2 		$3.73M Buy
90,970
+84,468
+1,299% +$4.35M ﹤0.01% 2025
2014
Q1 		$447K Sell
6,502
-4,255
-40% -$312K ﹤0.01% 4068
2013
Q4 		$645K Sell
10,757
-3,762
-26% -$205K ﹤0.01% 3845
2013
Q3 		$871K Buy
14,519
+12,605
+659% +$894K ﹤0.01% 3508
2013
Q2 		$128K Buy
+1,914
New +$86.1K ﹤0.01% 5586

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Barclays's CLVS Position: Q4 2022 in Review

Barclays sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 132,775 shares — an estimated $158K sold.

Barclays first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $13M in Q4 2016. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Barclays reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 132,775 Clovis Oncology, Inc. shares in Q4 2022, an estimated $158K.
  • Barclays first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Barclays's Clovis Oncology, Inc. position peaked at $13M in Q4 2016.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.